Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: Study protocol for a randomized, parallel-group, non-inferiority trial

Yuma Yokoi, Atsuo Nakagawa, Naoki Yoshimura, Toshiaki A. Furukawa, Masaru Mimura, Akira Iwanami, Takayuki Abe, Kazuyuki Nakagome

Research output: Contribution to journalArticle

Abstract

Aim: The purpose of this study is to compare acceptability of two second generation antidepressants for major depressive disorder patients who have not responded to the first antidepressant for current episode. We will investigate the treatment discontinuation rate and treatment adherence as well as incidence of adverse events in order to evaluate safety. Methods: This is a two-arm, three-phased randomized controlled trial in which independent assessors will be blinded while treating psychiatrists and patients remain unblinded to treatment allocation. Patients will be randomized to escitalopram or duloxetine in Step 1 (8 weeks), and when entering Step 2 (8 weeks), the drug will be switched to the other if the first one is not effective at the end of Step 1. The acceptability of the allocated drugs, improvements in depression from baseline, adverse events, and attrition rates will be recorded and assessed for up to 52 weeks, including the follow-up step. Results: It is going to be disseminated via our following reports or presentations. Conclusions: This study will provide valuable information for clinicians who encounter patients who failed to respond to their first treatment.

Original languageEnglish
JournalNeuropsychopharmacology Reports
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Citalopram
Antidepressive Agents
Outpatients
Depression
Major Depressive Disorder
Therapeutics
Pharmaceutical Preparations
Psychiatry
Randomized Controlled Trials
Safety
Duloxetine Hydrochloride
Incidence

Keywords

  • acceptability
  • antidepressants
  • duloxetine
  • escitalopram
  • randomized controlled trial

ASJC Scopus subject areas

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants : Study protocol for a randomized, parallel-group, non-inferiority trial. / Yokoi, Yuma; Nakagawa, Atsuo; Yoshimura, Naoki; Furukawa, Toshiaki A.; Mimura, Masaru; Iwanami, Akira; Abe, Takayuki; Nakagome, Kazuyuki.

In: Neuropsychopharmacology Reports, 01.01.2019.

Research output: Contribution to journalArticle

@article{e31462049aca4291bf839992cecd6110,
title = "Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: Study protocol for a randomized, parallel-group, non-inferiority trial",
abstract = "Aim: The purpose of this study is to compare acceptability of two second generation antidepressants for major depressive disorder patients who have not responded to the first antidepressant for current episode. We will investigate the treatment discontinuation rate and treatment adherence as well as incidence of adverse events in order to evaluate safety. Methods: This is a two-arm, three-phased randomized controlled trial in which independent assessors will be blinded while treating psychiatrists and patients remain unblinded to treatment allocation. Patients will be randomized to escitalopram or duloxetine in Step 1 (8 weeks), and when entering Step 2 (8 weeks), the drug will be switched to the other if the first one is not effective at the end of Step 1. The acceptability of the allocated drugs, improvements in depression from baseline, adverse events, and attrition rates will be recorded and assessed for up to 52 weeks, including the follow-up step. Results: It is going to be disseminated via our following reports or presentations. Conclusions: This study will provide valuable information for clinicians who encounter patients who failed to respond to their first treatment.",
keywords = "acceptability, antidepressants, duloxetine, escitalopram, randomized controlled trial",
author = "Yuma Yokoi and Atsuo Nakagawa and Naoki Yoshimura and Furukawa, {Toshiaki A.} and Masaru Mimura and Akira Iwanami and Takayuki Abe and Kazuyuki Nakagome",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/npr2.12078",
language = "English",
journal = "Neuropsychopharmacology Reports",
issn = "1340-2544",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants

T2 - Study protocol for a randomized, parallel-group, non-inferiority trial

AU - Yokoi, Yuma

AU - Nakagawa, Atsuo

AU - Yoshimura, Naoki

AU - Furukawa, Toshiaki A.

AU - Mimura, Masaru

AU - Iwanami, Akira

AU - Abe, Takayuki

AU - Nakagome, Kazuyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: The purpose of this study is to compare acceptability of two second generation antidepressants for major depressive disorder patients who have not responded to the first antidepressant for current episode. We will investigate the treatment discontinuation rate and treatment adherence as well as incidence of adverse events in order to evaluate safety. Methods: This is a two-arm, three-phased randomized controlled trial in which independent assessors will be blinded while treating psychiatrists and patients remain unblinded to treatment allocation. Patients will be randomized to escitalopram or duloxetine in Step 1 (8 weeks), and when entering Step 2 (8 weeks), the drug will be switched to the other if the first one is not effective at the end of Step 1. The acceptability of the allocated drugs, improvements in depression from baseline, adverse events, and attrition rates will be recorded and assessed for up to 52 weeks, including the follow-up step. Results: It is going to be disseminated via our following reports or presentations. Conclusions: This study will provide valuable information for clinicians who encounter patients who failed to respond to their first treatment.

AB - Aim: The purpose of this study is to compare acceptability of two second generation antidepressants for major depressive disorder patients who have not responded to the first antidepressant for current episode. We will investigate the treatment discontinuation rate and treatment adherence as well as incidence of adverse events in order to evaluate safety. Methods: This is a two-arm, three-phased randomized controlled trial in which independent assessors will be blinded while treating psychiatrists and patients remain unblinded to treatment allocation. Patients will be randomized to escitalopram or duloxetine in Step 1 (8 weeks), and when entering Step 2 (8 weeks), the drug will be switched to the other if the first one is not effective at the end of Step 1. The acceptability of the allocated drugs, improvements in depression from baseline, adverse events, and attrition rates will be recorded and assessed for up to 52 weeks, including the follow-up step. Results: It is going to be disseminated via our following reports or presentations. Conclusions: This study will provide valuable information for clinicians who encounter patients who failed to respond to their first treatment.

KW - acceptability

KW - antidepressants

KW - duloxetine

KW - escitalopram

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=85073958115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073958115&partnerID=8YFLogxK

U2 - 10.1002/npr2.12078

DO - 10.1002/npr2.12078

M3 - Article

C2 - 31531962

AN - SCOPUS:85073958115

JO - Neuropsychopharmacology Reports

JF - Neuropsychopharmacology Reports

SN - 1340-2544

ER -